Dendritic cell-based immunotherapy: State of the art and beyond

Kalijn F. Bol, Gerty Schreibelt, Winald R. Gerritsen, I. Jolanda M. De Vries, Carl G. Figdor

Research output: Contribution to journalArticlepeer-review

Abstract

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective antitumor immune response against tumor antigens and was first explored in a clinical trial in the 1990s. More than two decades later, numerous clinical trials have been performed or are ongoing with a wide variety of DC subsets, culture protocols, and treatment regimens. The safety of DC vaccination and its ability to induce antitumor responses have clearly been established; however, although scattered patients with long-term benefit were reported, DC vaccines have not yet fulfilled their promise, perhaps mainly due to the lack of large-scale well-conducted phase II/III trials. To allow meaningful multicenter phase III trials, the production of DC vaccines should be standardized between centers which is now becoming feasible. To improve the efficacy of DC-based immunotherapy, it could be combined with other treatments.

Original languageEnglish (US)
Pages (from-to)1897-1906
Number of pages10
JournalClinical Cancer Research
Volume22
Issue number8
DOIs
StatePublished - Apr 15 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dendritic cell-based immunotherapy: State of the art and beyond'. Together they form a unique fingerprint.

Cite this